Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Substantial Decline in Prevalence of Vaccine-Type and Nonvaccine-Type Human Papillomavirus (HPV) in Vaccinated and Unvaccinated Girls 5 Years After Implementing HPV Vaccine in Norway.

Feiring B, Laake I, Christiansen IK, Hansen M, Stålcrantz J, Ambur OH, Magnus P, Jonassen CM, Trogstad L.

J Infect Dis. 2018 Nov 5;218(12):1900-1910. doi: 10.1093/infdis/jiy432.

2.

Prophylactic Vaccines Against Human Papillomavirus [Internet].

Klemp Gjertsen M, Nilsen E, Alfsen GC, Feiring B, Skjeldestad FE, Steen R, Sæterdal I.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2007 Jan.

3.

No conflicting results in the article "HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: A nationwide register-based study from Norway".

Feiring B, Laake I, Trogstad L.

Vaccine. 2017 Dec 18;35(51):7082-7083. doi: 10.1016/j.vaccine.2017.09.041. No abstract available.

PMID:
29195611
4.

Human papillomavirus prevalence and type distribution in urine samples from Norwegian women aged 17 and 21 years: A nationwide cross-sectional study of three non-vaccinated birth cohorts.

Molden T, Feiring B, Ambur OH, Christiansen IK, Hansen M, Laake I, Meisal R, Myrvang E, Jonassen CM, Trogstad L.

Papillomavirus Res. 2016 Dec;2:153-158. doi: 10.1016/j.pvr.2016.05.002. Epub 2016 May 20.

5.

HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: A nationwide register-based study from Norway.

Feiring B, Laake I, Bakken IJ, Greve-Isdahl M, Wyller VB, Håberg SE, Magnus P, Trogstad L.

Vaccine. 2017 Jul 24;35(33):4203-4212. doi: 10.1016/j.vaccine.2017.06.031. Epub 2017 Jun 23.

6.

Do selective immunisation against tuberculosis and hepatitis B reach the targeted populations? A nationwide register-based study evaluating the recommendations in the Norwegian Childhood Immunisation Programme.

Feiring B, Laake I, Molden T, Håberg SE, Nøkleby H, Seterelv SS, Magnus P, Trogstad L.

Vaccine. 2016 Apr 12;34(17):2015-20. doi: 10.1016/j.vaccine.2016.02.060. Epub 2016 Mar 3.

PMID:
26947498
7.

Do parental education and income matter? A nationwide register-based study on HPV vaccine uptake in the school-based immunisation programme in Norway.

Feiring B, Laake I, Molden T, Cappelen I, Håberg SE, Magnus P, Steingrímsdóttir ÓA, Strand BH, Stålcrantz J, Trogstad L.

BMJ Open. 2015 May 19;5(5):e006422. doi: 10.1136/bmjopen-2014-006422.

8.

Risk of fetal death after pandemic influenza virus infection or vaccination.

Håberg SE, Trogstad L, Gunnes N, Wilcox AJ, Gjessing HK, Samuelsen SO, Skrondal A, Cappelen I, Engeland A, Aavitsland P, Madsen S, Buajordet I, Furu K, Nafstad P, Vollset SE, Feiring B, Nøkleby H, Magnus P, Stoltenberg C.

N Engl J Med. 2013 Jan 24;368(4):333-40. doi: 10.1056/NEJMoa1207210. Epub 2013 Jan 16.

9.

The Norwegian immunisation register--SYSVAK.

Trogstad L, Ung G, Hagerup-Jenssen M, Cappelen I, Haugen IL, Feiring B.

Euro Surveill. 2012 Apr 19;17(16). pii: 20147.

10.

Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway.

Guzmán Herrador BR, Aavitsland P, Feiring B, Riise Bergsaker MA, Borgen K.

BMC Infect Dis. 2012 Mar 20;12:63. doi: 10.1186/1471-2334-12-63.

11.

Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.

Sandbu S, Feiring B, Oster P, Helland OS, Bakke HS, Naess LM, Aase A, Aaberge IS, Kristoffersen AC, Rydland KM, Tilman S, Nøkleby H, Rosenqvist E.

Clin Vaccine Immunol. 2007 Sep;14(9):1062-9. Epub 2007 Jul 18.

12.

Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.

Nøkleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P.

Vaccine. 2007 Apr 20;25(16):3080-4. Epub 2007 Jan 22.

PMID:
17287053
13.

[The Norwegian vaccination program].

Nøkleby H, Feiring B.

Tidsskr Nor Laegeforen. 2006 Oct 5;126(19):2538-40. Norwegian.

14.

Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine.

Feiring B, Fuglesang J, Oster P, Naess LM, Helland OS, Tilman S, Rosenqvist E, Bergsaker MA, Nøkleby H, Aaberge IS.

Clin Vaccine Immunol. 2006 Jul;13(7):790-6.

15.

Introduction of pneumococcal conjugate vaccine into the Norwegian childhood vaccination programme.

Bergsaker MA, Feiring B.

Euro Surveill. 2006 Feb 2;11(2):E060202.5. No abstract available.

PMID:
16804205
16.

Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks.

Taha MK, Zarantonelli ML, Alonso JM, Naess LM, Holst J, Feiring B, Rosenqvist E.

Vaccine. 2007 Mar 30;25(14):2537-8. Epub 2006 Jan 20. No abstract available.

PMID:
16460845
17.

Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control.

Thornton V, Lennon D, Rasanathan K, O'Hallahan J, Oster P, Stewart J, Tilman S, Aaberge I, Feiring B, Nokleby H, Rosenqvist E, White K, Reid S, Mulholland K, Wakefield MJ, Martin D.

Vaccine. 2006 Feb 27;24(9):1395-400. Epub 2005 Oct 4.

PMID:
16242221
18.

Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic.

Aaberge IS, Oster P, Helland OS, Kristoffersen AC, Ypma E, Høiby EA, Feiring B, Nøkleby H.

Clin Diagn Lab Immunol. 2005 May;12(5):599-605.

19.

The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease.

Holst J, Feiring B, Naess LM, Norheim G, Kristiansen P, Høiby EA, Bryn K, Oster P, Costantino P, Taha MK, Alonso JM, Caugant DA, Wedege E, Aaberge IS, Rappuoli R, Rosenqvist E.

Vaccine. 2005 Mar 18;23(17-18):2202-5.

PMID:
15755595
20.

Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease.

Holst J, Feiring B, Fuglesang JE, Høiby EA, Nøkleby H, Aaberge IS, Rosenqvist E.

Vaccine. 2003 Jan 30;21(7-8):734-7.

PMID:
12531351
21.

[Should school children receive pertussis vaccine?].

Sandbu S, Nøkleby H, Helland OS, Feiring B, Bondevik M, Sundelin F, Storsaeter J.

Tidsskr Nor Laegeforen. 2001 May 10;121(12):1464-8. Norwegian.

22.

The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials.

Nøkleby H, Feiring B.

NIPH Ann. 1991 Dec;14(2):95-101; discussion 101-2.

PMID:
1812440
23.

Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey.

Høiby EA, Rosenqvist E, Frøholm LO, Bjune G, Feiring B, Nøkleby H, Rønnild E.

NIPH Ann. 1991 Dec;14(2):147-55; discussion 155-6.

PMID:
1812429
24.

Human antibody responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine: results from ELISA studies.

Rosenqvist E, Høiby EA, Bjune G, Bryn K, Closs O, Feiring B, Klem A, Nøkleby H, Frølm LO.

NIPH Ann. 1991 Dec;14(2):169-79; discussion 180-1.

PMID:
1687481
25.

[Clinical trials of antineoplastic agents reported to the Norwegian Drug Control Authority during the period 1982-1986].

Furu K, Feiring B.

Tidsskr Nor Laegeforen. 1989 Jan 30;109(3):317-9. Norwegian.

PMID:
2916213
26.

[Clinical trials reported to the Norwegian Drug Control Authority during the period 1982-1986].

Feiring B, Furu K.

Tidsskr Nor Laegeforen. 1989 Jan 30;109(3):313-6. Norwegian.

PMID:
2916212

Supplemental Content

Loading ...
Support Center